Life-science briefing: Thursday, March 20, 2008
TODAY’S HEADLINES:
Vantia Thera spins out of Ferring, raises £19M (PDF release)
Third Eye gets $150K for intracranial-pressure monitor (release)
Diabetes tester Oculir closes doors, returns capital (VentureWire)
Catalyst Health Ventures raising $60M fund (VentureWire)
Vantia Thera spins out of Ferring, raises £19M – Vantia Therapeutics, a U.K. spinout of Ferring Pharmaceuticals, has launched and raised £19 million ($37.7 million) in a first funding round (PDF link). Investors included MVM Life Science Partners, SV Life Sciences and Novo A/S.
Vantia inherits a… Continue Reading
Life sciences briefing: Friday, Sept. 14, 2007
Featured companies: Accenx, Chlorogen, Third Rock Ventures
Ex-Millennium execs found new life-sciences venture fund, raise $378M — Several former executives of Millennium Pharmaceuticals have founded a new Boston-based venture firm called Third Rock Ventures and raised $378 million for early-stage investments.
The Millennium connection runs so deep you’d be forgiven for thinking the company had simply spun out a venture-capital arm. Third Rock’s partners include Millennium founder and former CEO Mark Levin; former Millennium CFO Kevin Starr;… Continue Reading